Stoke Therapeutics (STOK) Non-Current Deffered Revenue (2022 - 2026)

Stoke Therapeutics' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 35.61% year-over-year to $6.6 million in Q1 2026; TTM through Mar 2026 was $6.6 million, a 35.61% decrease from a year earlier, with the FY2025 full-year figure at $7.0 million, changed N/A from the prior year.
• Non-Current Deffered Revenue declined to $6.6 million in Q1 2026 per STOK's latest filing, from $7.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $49.5 million in Q1 2022 and bottomed at $6.6 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $29.1 million (2023), against an average of $26.0 million.
• Across the five-year window, Non-Current Deffered Revenue slumped 79.64% in 2024 and advanced 3.22% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $36.9 million in 2022, then slipped by 10.26% to $33.1 million in 2023, then tumbled by 74.93% to $8.3 million in 2024, then slipped by 16.04% to $7.0 million in 2025, then decreased by 5.14% to $6.6 million in 2026.
• Per Business Quant, the three latest STOK Non-Current Deffered Revenue figures stand at $6.6 million (Q1 2026), $7.0 million (Q4 2025), and $8.6 million (Q3 2025).